Get the Stockscreener App
1.83
3.98%
0.07
After Hours:
1.80
-0.03
-1.64%
Tuhura Biosciences Inc stock is traded at $1.83, with a volume of 86,311.
It is up +3.98% in the last 24 hours and down -9.85% over the past month.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
See More
Previous Close:
$1.76
Open:
$1.74
24h Volume:
86,311
Relative Volume:
0.40
Market Cap:
$116.62M
Revenue:
Net Income/Loss:
$-30.92M
P/E Ratio:
-3.0353
EPS:
-0.6029
Net Cash Flow:
$-27.39M
1W Performance:
-5.18%
1M Performance:
-9.85%
6M Performance:
-40.39%
1Y Performance:
-28.52%
1-Day Range:
$1.74
$1.84
1-Week Range:
$1.7107
$1.99
52-Week Range:
$0.41
$3.43
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.83 | 116.62M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
Hon Donald Sternoff Beyer Jr Stock Trades and Disclosures - TechGraph
A cancer patent also covers cell-based treatments, not just antibody-linked drugs - Stock Titan
TuHURA Biosciences (Nasdaq:HURA)Stock Analysis - Simply Wall Street
A cancer drug company CEO will speak in New York on Sept. 14 - Stock Titan
TuHURA Biosciences to Present at Investment Conference - Intellectia AI
TuHURA Biosciences Inc (NASDAQ: HURA) Share Price, HURA Stock News, HURA Share Price & Updates - Kalkine
TuHURA Biosciences draws additional funds from credit facility - TipRanks
HURA: Milestone Progression Over Next 12 Months - Yahoo Finance
TuHURA Biosciences Inc (NASDAQ: HURA) Share Price, HURA Stock News, HURA Share Price & Updates - kalkine.ca
TuHURA Biosciences | 8-K: Current report - Moomoo
H.C. Wainwright Maintains TuHURA Biosciences(HURA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com South Africa
TuHURA (HURA) Technicals: Closes 5.56% Higher at $2.28 in the Latest Session; Boundary Watch: the Supplied Trading Band Runs From $2.17 to $2.39Breakout Confirmation - dars.gov.et
TuHURA (HURA) Technicals: Closes 5.56% Higher at $2.28 in the Latest Session; Boundary Watch: the Supplied Trading Band Runs From $2.17 to $2.39Demand Zone - vinanet.vn
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com Nigeria
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com South Africa
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com Canada
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com India
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com Canada
TuHURA Biosciences | 8-K: Current report - Moomoo
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com UK
HURA: All proposals passed, including director elections and share issuance, with no stockholder questions - TradingView
HURA: All proposals, including director elections and share issuance, were approved without dissent - TradingView
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com Nigeria
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com India
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com Canada
HURA Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Jump 7.4%Low Estimate Range - vinanet.vn
TuHURA Biosciences Extends Runway as Immuno-Oncology Pipeline Advances - TipRanks
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord - MarketBeat
TuHURA Biosciences, Inc.Common Stock (HURA) Stock Price, News, Quote & History - FinancialContent
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord - Yahoo Finance
TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY - scanx.trade
TuHURA Secures $50M Credit Facility Extending Cash Runway into 2028 - Minichart
Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update - TradingView
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com Nigeria
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com Canada
TuHURA Biosciences (HURA) deepens R&D spend and adds $50M credit facility - Stock Titan
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com India
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com UK
TuHURA Reports $1.0 Million Cash and Advances TBS-2025 AML Program - Quiver Quantitative
TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway - TradingView
TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA - Moomoo
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences Expands Use of Revolving Credit Facility - TipRanks
TuHURA Biosciences (HURA) Earnings Date and Reports 2026 - marketbeat.com
TuHURA at canaccord growth conference: late-stage push gains traction By Investing.com - Investing.com Nigeria
Tuhura Biosciences Inc Stock (HURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):